SAV

SAV(SAV)股票分析

$24.750

+0.020 (+0.08%)收盘时

Loading chart…
最高
24.800
开盘
24.800
成交量加权均价
24.75
成交量
1.58K
市值
—
最低
24.688
成交额
39.17K
企业价值/息税折旧摊销前利润(TTM)
—

AI 分析 of SAV (SAV)

买入

Cassava Sciences Inc (SAVA) appears to be a good buy right now, especially considering its current price of 2.38, which is well below its 52-week high of 3.45. The recent closure of the DOJ investigation and the company's strategic rebranding to Filana Therapeutics are positive catalysts that could enhance investor confidence. Additionally, the RSI is at 66.474, indicating strong momentum, while the stock has seen a 16.10% increase over the last 20 days, suggesting a bullish trend. However, the main risk is the company's negative net income, which was -44224000 in Q2 2025, highlighting ongoing financial challenges that investors should monitor closely.

SAV 常见问题 —— 由 Alphio AI 解答

Cassava Sciences Inc (SAVA) appears to be a good buy right now, especially considering its current price of 2.38, which is well below its 52-week high of 3.45. The recent closure of the DOJ investigation and the company's strategic rebranding to Filana Therapeutics are positive catalysts that could enhance investor confidence. Additionally, the RSI is at 66.474, indicating strong momentum, while the stock has seen a 16.10% increase over the last 20 days, suggesting a bullish trend. However, the main risk is the company's negative net income, which was -44224000 in Q2 2025, highlighting ongoing financial challenges that investors should monitor closely.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易